/
/
/

Senores Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
₹180 Cr₹175 Cr₹175 Cr₹162 Cr₹133 Cr₹114 Cr₹103 Cr₹101 Cr₹80 Cr₹102 Cr₹79 Cr
₹3 Cr₹18 Cr₹4 Cr₹5 Cr₹9 Cr₹12 Cr₹5 Cr₹2 Cr₹48 L₹2 Cr₹80 L
₹183 Cr₹193 Cr₹178 Cr₹167 Cr₹141 Cr₹126 Cr₹108 Cr₹102 Cr₹81 Cr₹104 Cr₹80 Cr
₹136 Cr₹137 Cr₹128 Cr₹120 Cr₹110 Cr₹100 Cr₹82 Cr₹81 Cr₹63 Cr₹84 Cr₹67 Cr
₹57 Cr₹65 Cr₹58 Cr₹55 Cr₹38 Cr₹31 Cr₹31 Cr₹25 Cr₹22 Cr₹24 Cr₹16 Cr
₹7 Cr₹8 Cr₹5 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹5 Cr₹5 Cr₹3 Cr₹2 Cr
₹39 Cr₹47 Cr₹45 Cr₹41 Cr₹26 Cr₹21 Cr₹20 Cr₹16 Cr₹13 Cr₹18 Cr₹10 Cr
₹30 Cr₹37 Cr₹34 Cr₹30 Cr₹21 Cr₹18 Cr₹16 Cr₹13 Cr₹11 Cr₹14 Cr₹7 Cr

Share Price Live Stats

Open (₹)1,442.80
Volume (₹)82,317.00
High (₹)1,465.90
Upper Circuit1,716.40
Low (₹)1,427.60
Lower Circuit1,144.40
Prev Close1,430.40
52W High (₹)1,599.00
Price1,430.70
52W Low (₹)662.45

Share Market Cap & Key Ratios Overview

M.Cap (₹)6596.95 Cr
Div. Yield (%)0.00
PE Ratio52.20
Debt to Equity0.39
Price to Book3.35
Book Value170.72
EPS (TTM)27.44
Face Value10.00
ROE (%)11.78

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
SENORESNSE
LTP
1W Low
1W High
Market cap (₹)
1902.1-17.9 (-0.93%)
1900.10
1984.80
4,56,833Cr
9182.5-56.5 (-0.61%)
9087
9467
2,45,426Cr
4863.5-186.5 (-3.69%)
4863
5066
1,87,320Cr
1132.2-58.8 (-4.94%)
1125.10
1187
1,13,217Cr
1380-43.5 (-3.06%)
1376.70
1426.10
1,12,212Cr
1855.9-82.6 (-4.26%)
1811.70
1949
1,01,155Cr
2124.2-47.3 (-2.18%)
2118.10
2192
97,626Cr
2337.5-45.4 (-1.91%)
2336.10
2419.20
96,859Cr
1163-15 (-1.27%)
1154.40
1179.90
96,406Cr
1657.4+12.1 (0.74%)
1622.60
1717
93,614Cr
1430.7-51.4 (-3.47%)
1423.10
1500.10
6,597Cr

Key Highlights of Senores Pharmaceuticals Ltd’s P&L

In 2025-03-31, Senores Pharmaceuticals Ltd reported total revenue of ₹417.58Cr, compared with ₹217.34Cr in 2024-03-31, reflecting Senores Pharmaceuticals Ltd turnover.

Depreciation was ₹16.84Cr and finance costs were ₹21.55Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹70.57Cr in 2025-03-31 as compared to ₹24.94Cr in 2024-03-31.

Net Profit (PAT) was ₹58.56Cr in 2025-03-31 compared with ₹31.46Cr in 2024-03-31.

Earnings per share (EPS) were ₹12.72 in 2025-03-31, compared with ₹10.31 in 2024-03-31.